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FOXO transcription factors are evolutionarily conserved
proteins that orchestrate gene expression programs known
to control a variety of cellular processes such as cell cycle,
apoptosis, DNA repair and protection from oxidative
stress. As the abrogation of FOXO function is a key
feature of many tumor cells, regulation of FOXO factors
is receiving increasing attention in cancer research. In
order to discover genes involved in the regulation
of FOXO activity, we performed a large-scale RNA-
mediated interference (RNAi) screen using cell-based
reporter systems that monitor transcriptional activity
and subcellular localization of FOXO. We identiﬁed genes
previously implicated in phosphoinositide 3-kinase/Akt
signaling events, which are known to be important for
FOXO function. In addition, we discovered a previously
unrecognized FOXO-repressor function of TRIB2, the
mammalian homolog of the Drosophila gene tribbles.
A cancer-proﬁling array revealed speciﬁc overexpression
of TRIB2 in malignant melanoma, but not in other types
of skin cancer. We provide experimental evidence that
TRIB2 transcript levels correlate with the degree of
cytoplasmic localization of FOXO3a. Moreover, we show
that TRIB2 is important in the maintenance of the
oncogenic properties of melanoma cells, as its silencing
reduces cell proliferation, colony formation and wound
healing. Tumor growth was also substantially reduced
upon RNAi-mediated TRIB2 knockdown in an in vivo
melanoma xenograft model. Our studies suggest that
TRIB2 provides the melanoma cells with growth and
survival advantages through the abrogation of FOXO
function. Altogether, our results show the potential of
large-scale cell-based RNAi screens to identify promising
diagnostic markers and therapeutic targets.
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Introduction
FOXO transcription factors are bona ﬁde tumor suppres-
sors that are inactivated in the majority of human cancers,
owing to the overactivation of the phosphoinositide
3-kinase (PI3K)/Akt pathway (Dansen and Burgering,
2008). The four members of the mammalian FOXO
family of proteins—FOXO1, FOXO3a, FOXO4 and
FOXO6—belong to class O of the forkhead/winged helix
transcription factors (Fox). FOXO proteins can regulate a
variety of genes that inﬂuence cell proliferation, survival,
metabolism and response to stress (Huang and Tindall,
2007). The FOXOs are regulated by synthesis, phosphor-
ylation, acetylation and ubiquitination at three different
levels: subcellular localization, stability and transcrip-
tional activity (Myatt and Lam, 2007). Upon the acti-
vation of PI3K/Akt signaling, FOXOs undergo Akt-
mediated phosphorylation, which promotes binding to
14-3-3, nuclear export through CRM1 and cytoplasmic
sequestration. Under stress conditions or in the absence of
growth or survival factors, when the PI3K/Akt pathway is
inhibited, FOXO proteins translocate to the cell nucleus,
where their transcriptional functions can be executed
(Brunet et al., 1999).
Triple knockout mouse models proved the tumor
suppressor properties of FOXOs, as mice simulta-
neously lacking the principal members of the mamma-
lian FoxO subfamily, FoxO1, FoxO3a and FoxO4, are
prone to develop hemangiomas and lymphoproliferative
diseases (Paik et al., 2007). Conversely, the individual or
paired inactivation of FoxO1, FoxO3a or FoxO4
resulted in a less severe phenotype, supporting the idea
of functional redundancy of these FOXO factors (Paik
et al., 2007). Furthermore, forced expression of FOXO
has been shown to curb tumorigenesis in xenograft
experiments using human tumor cell lines grown in nude
mice (Hu et al., 2004; Yang et al., 2005). Therefore,
reactivation of FOXO based on its tumor suppressor
properties is considered as a very attractive anti-cancer
strategy. Contrary to other tumor suppressors such as
p53 or PTEN, the functions of which are abrogated
by genetic or epigenetic changes, inactivation of
FOXOs occurs mostly because of the overactivation of
their inhibitory inputs (Dansen and Burgering, 2008).
This offers a wide range of possibilities for restoring
FOXO activity with small-molecule inhibitors targeting
up-regulated FOXO repressors. Nevertheless, as FOXO
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also induces genes involved in resistance to cellular stress,
including the multi-drug resistance gene ABCB1 (Gomes
et al., 2008; Hui et al., 2008), such a strategy has to be
carefully evaluated and the most suitable points of
intervention must be identiﬁed. The transcriptional pro-
gram ﬁnally executed by FOXO is thought to be dependent
on the pattern of its post-transcriptional modiﬁcations
(Calnan and Brunet, 2008). Hence, characterization of the
components that participate in the signaling network that
controls the activity of FOXO is essential to reveal possible
therapeutic targets for future anticancer therapies. To
identify endogenous suppressors of FOXO, which could be
exploited pharmacologically to restore FOXO function in
human tumors, we conducted a systematic large-scale loss-
of-function screening. Among the genes identiﬁed and
validated as negative FOXO regulators, we found the
pseudokinase TRIB2. In vitro and in vivo results reported
here indicate that TRIB2 can facilitate the growth and
survival of melanomas by downregulating FOXO activity.
Results
Generation of the 293foxREP cell line
To establish a cell line capable of measuring the
transcriptional activity of FOXO and suitable for
a transfection-based RNA-mediated interference
(RNAi) screening, we introduced the reporter construct
pGLpuro-3xDBE (Zanella et al., 2009) into human
embryonic kidney (HEK)293T cells. pGLpuro-3xDBE
contains three copies of the DBE consensus cassette
in front of an SV40 minimal viral promoter linked to
a ﬁreﬂy luciferase reporter gene and a puromycin-
resistance cassette (Supplementary Figure S1A). Stable
293foxREP cells showed a strong responsiveness to
inhibition of the PI3K/Akt pathway (Supplementary
Figure S1B) and hence proved to be suitable tools to
screen for the interference with FOXO regulation.
Screening of an RNAi library against 7914 human genes
The identiﬁcation of all components involved in the
regulatory network that determines the activity of
FOXO proteins is an essential step to develop targeted
therapies that reactivate speciﬁc FOXO functions in
human tumors. Hence, we performed a large-scale loss-
of-function screen aimed at the identiﬁcation of genes
that suppress the transcriptional activity and nuclear
localization of FOXO transcription factors (Supplemen-
tary Figure S2). We used a vector-based RNAi library
against 7914 human genes, each of them targeted by a
pool of three different short hairpin RNA (shRNA),
which has been widely used for target discovery efforts
(Berns et al., 2004). We cotransfected each shRNA pool
along with a constitutive expression vector containing
the FOXO gene and another containing the Renilla
luciferase gene into 293foxREP cells and monitored the
ﬁreﬂy luciferase activity normalized against Renilla
luciferase. Those shRNAs pools that generated a
normalized luciferase activity greater than threefold
the activity of the control shRNA vector were analyzed
for its capacity to induce nuclear translocation of
FOXO in the U2foxRELOC system that has been
described previously (Zanella et al., 2008). Brieﬂy,
U2foxRELOC cells stably express a green ﬂuorescent
protein-tagged version of FOXO3a to monitor the
subcellular localization of FOXO proteins. We prior-
itized those hits scoring positive in both 293foxREP and
U2foxRELOC cells (Supplementary Table S1). Among
these dual hits were several genes known to be part of
the PI3K/Akt network, including PIK3CA and Akt-3,
indicating the speciﬁcity of our screening strategy.
Importantly, several genes previously not associated
with the regulation of FOXO activity were identiﬁed.
Validation of TRIB2 silencing
The RNAi-mediated silencing of TRIB2, the human
homolog of the Drosophila gene tribbles, resulted in the
induction of FOXO-dependent transcription in 293fox-
REP cells and the nuclear translocation of FOXO3a
in U2foxRELOC cells. We isolated and veriﬁed the
sequences of the three components of the corresponding
shRNA pool. Quantitative PCR analysis revealed that
two of the three shRNAs of the pool were capable of
silencing TRIB2 transcript levels. To validate our ﬁndings
using independent RNAi agents against TRIB2, we
analyzed several siRNA oligonucleotides as well as
vector-based shRNA constructs for their silencing efﬁ-
ciency against TRIB2. These shRNAs and siRNAs were
chosen to contain different 50-portions of the guide strand
that has been implicated in unintended transcript silencing
(Birmingham et al., 2006). Several RNAi-based agents
effectively reduced the expression of TRIB2 (Supplemen-
tary Table S2). Two different vector-based shRNA
constructs—TRIB2NKI shRNA and TRIB2ORI shRNA—
proved to be the most efﬁcient tools to silence TRIB2
and were used for further analysis. Figure 1a shows the
reduction of TRIB2 mRNA upon the transfection of
HEK293T cells with TRIB2NKI shRNA as compared
with cells transfected with the corresponding control
vector. Importantly, transient expression of the TRIB2NKI
shRNA resulted in increased FOXO-driven luciferase
activity (Figure 1b) and nuclear localization of GFP–
FOXO (Figures 1c and d). In contrast, unrelated shRNA
sequences failed to produce similar effects on FOXO
(data not shown). On the other hand, the overexpression
of a V5-tagged version of TRIB2, which was detected by
western blot analysis using a V5-speciﬁc antibody
(Figure 2a), markedly decreased FOXO-driven luciferase
activity in 293foxREP cells (Figure 2b). Silencing or
overexpression of TRIB2 produced very similar effects on
FOXO family member FOXO1 (data not shown). These
results suggest that TRIB2 acts as a FOXO repressor,
promoting its cytoplasmic sequestration and impairing its
transcriptional control function.
TRIB2 transcript levels are elevated in malignant
melanoma
The implication of TRIB2 in the regulation of the tumor
suppressor FOXO prompted us to analyze its expression
levels in human tumors. To that end, we used a cancer
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proﬁling array containing samples from 154 patients
with different tumors, including the breast, ovary, colon,
stomach, lung, kidney, bladder, vulva, prostate, uterus,
cervix, rectum, thyroid, testis, skin, small intestine and
pancreas. For this array, complementary DNAs
(cDNA) generated from matched normal and tumor
tissue samples from individual patients had been spotted
side by side on a nylon membrane. In addition, cDNAs
from nine different cancer cell lines have been included
(Supplementary Figure S3). Interestingly, elevated levels
of TRIB2 mRNA were observed in 7 out of 10 skin
cancer samples (Figures 3a and b). Moreover, the seven
samples that showed high TRIB2 expression correspond
to malignant melanoma lesions (Figure 3a: P1–P5, P9,
P10), whereas the remaining three samples (Figure 3a:
P6, P7 and P8) that did not show a signiﬁcant increase
of TRIB2 transcripts refer to squamous-cell carcinomas
(Supplementary Table S3). Consistently, we detected the
highest level of TRIB2 transcripts in G-361 melanoma
cells when compared with eight other non-melanoma
cells represented on the same membrane (Figures 3c and
d). To conﬁrm this observation, we analyzed an
independent arrayed panel of 43 pre-normalized cDNAs
selected from normal and melanoma tissues and from
mixed ages and genders (Supplementary Table S4).
qRT–PCR analysis of these samples revealed a sig-
niﬁcantly increased level of TRIB2 expression in
malignant melanoma diagnosed at stage III or IV when
compared with normal skin tissues (Supplementary
Figure S2C). The same pattern was reproduced when
the mRNA level of TRIB2 was analyzed in a panel of
melanoma cell lines versus non-melanoma cell lines
by qRT–PCR. We detected an abundance of TRIB2
transcripts between 3 and 23 times greater in cell
lines derived from melanoma biopsies than in non-
melanoma cells including keratinocytes and ﬁbro-
blasts (Figure 4a). Interestingly, human epidermal
melanocytes also showed high levels of TRIB2 tran-
scripts. The levels of Bim, a pro-apoptotic molecule
transcriptionally regulated by FOXO, were also
assessed. We observed an inverse correlation between
the transcript levels of TRIB2 and Bim (Figure 4b).
In human epidermal melanocytes and melanoma cells,
high expression of TRIB2 coincides with very low
levels of Bim transcripts. In contrast, non-melanoma cell
lines with low level of TRIB2 transcription showed
increased abundance of Bim transcripts. Accordingly,
the levels of TRIB2 expression correlate with the
subcellular localization of ﬂuorescently labeled FOXO
reporter protein, which we introduced stably into
melanoma and non-melanoma cell lines (Figure 4c).
Taken together, these data suggest that overexpression
of TRIB2 leads to the reduction of FOXO activity in
melanocyte-derived cells.
TRIB2 knockdown increases the activity of FOXO
in melanoma
To assess the inﬂuence of TRIB2 on FOXO functions in
melanoma, G-361 human melanoma cells were adopted
as a model, as they show increased levels of TRIB2
mRNA (see above). G-361 cells stably expressing a
GFP–FOXO3a fusion protein and the FOXO-driven
luciferase reporter construct pGL3puro-3xDBE, here-
after designated as G-361FireFox, were transiently
transfected with shRNA agents against TRIB2, PIK3-
CA, Akt or their respective empty control plasmids.
A signiﬁcant increase in luciferase-produced lumines-
cence was detected upon silencing of TRIB2, coincident
with the nuclear relocalization of the GFP–FOXO
fusion protein. The effect obtained was comparable to
FOXO stimulation via the knockdown of PI3K or Akt
(Supplementary Figure S4). In contrast, unrelated
shRNA sequences failed to produce similar effects on
FOXO (data not shown). These data support the
hypothesis that TRIB2 may function as a FOXO
repressor and prove this G-361FireFox model to be
suitable to analyze the role of TRIB2 in malignant
melanoma.
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Figure 1 Silencing of TRIB2 induces FOXO-driven luciferase
activity and nuclear translocation of GFP–FOXO. (a) Relative
TRIB2/GAPDH mRNA levels after transfection of HEK293T cells
with the shRNA construct TRIB2_NKI. Cells were harvested 48 h
after transfection and processed for quantitative PCR using the
methods described above. (b) Transcriptional activity of FOXO
upon silencing of TRIB2 with the shRNA construct TRIB2_NKI
as measured by FOXO-driven expression of luciferase in co-
transfection experiments. Each construct was transiently co-
transfected with plasmids encoding FOXO3a and Renilla luciferase
into 293foxREP cells, and the luciferase activities were determined
as described in Materials and methods. The data were normalized
to the Renilla luciferase (phRG-TK vector) reporter construct. The
results are given as the mean±s.e.m. of three independent
experiments performed in triplicate. (c, d) Subcellular localization
of ﬂuorescent FOXO reporter protein after transfection of
U2foxRELOC cells with control vector (c) or shRNA construct
TRIB2_NKI (d).
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TRIB2 facilitates the growth and survival of melanoma
cells
In order to investigate the importance of TRIB2 for
melanoma cells, we developed a stable knockdown
system for TRIB2. G-361 melanoma cells were trans-
fected either with a control vector (361C) or with an
shRNA against TRIB2 (361shTRIB). TRIB2 mRNA
levels were monitored in several independent cell clones
expanded from single puromycin-resistant colonies after
stable transfection by qRT–PCR. Figure 5a shows that
continuous silencing of TRIB2 in 361shTRIB cells led to
a 10-fold decrease of TRIB2 mRNA compared with the
transcript level in 361C cells.
In order to explore the role of TRIB2-mediated
FOXO inactivation in melanoma, we assessed the
tumorigenic properties of the melanoma knockdown
system previously generated. 361C and 361shTRIB cells
were seeded and maintained in standard growth factor
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Figure 2 Ectopic expression of TRIB2 reduced FOXO-driven luciferase expression. (a) TRIB2 cDNA was tagged with a V5 epitope
and expressed in HEK293T cells. Overexpression was detected by western blot analysis using a speciﬁc antibody against the V5 tag.
Equal loading was conﬁrmed by the speciﬁc detection of a-tubulin expression. Relevant proteins are indicated by arrows in the blot
from a representative experiment. (b) Luciferase expression from a FOXO-driven promoter was monitored upon expression of control
plasmid or V5-tagged TRIB2 cDNA. Each construct was transiently co-transfected with plasmids encoding FOXO3a and Renilla
luciferase into 293foxREP cells, and the luciferase activities were determined as described above. The data were normalized to the
Renilla luciferase (phRG-TK vector) reporter construct. The results are given as the mean±s.e.m. of three independent experiments
performed in triplicate.
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Figure 3 TRIB2 is overexpressed in malignant melanoma. A cancer-proﬁling array was hybridized separately with a radiolabeled
probe for the housekeeping gene ubiquitin and a radiolabeled probe for TRIB2. Hybridization signals were detected by
phosphoimaging. (a) Samples from 10 patients (P1–P10) with skin cancer and matched normal tissue are shown. N¼normal;
T¼ tumor. (b) Quantiﬁcation of TRIB2 levels was performed using Quantity One software. The hybridization signals for TRIB2 were
normalized against signals obtained for ubiquitin. Then, the ratio between normalized values from normal tissue to those from tumors
was calculated for each patient (P1–P10). Black bars represent malignant melanoma, white bars indicate non-melanoma skin cancer.
(c) Hybridization signals from nine different cancer cell lines were shown. (d) Quantiﬁcation of TRIB2 levels was performed as
described above. Black bars represent melanoma cells; dashed bars indicate non-melanoma cancer cell lines.
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conditions, while cell growth was monitored every other
day by crystal violet staining. The absorbance of the cell
lysis products was taken as an indirect measurement of
the cell growth. 361shTRIB cells showed a signiﬁcantly
decreased proliferation rate when compared with 361C
cells (Figure 5b), indicating that TRIB2 expression
confers growth advantage to those melanoma cells. To
determine whether TRIB2 inﬂuences the ability of
melanoma cells to overcome apoptosis in the absence
of cell contact, 104 361C or 361shTRIB cells were seeded
at low density and allowed to grow over a period of 10
days. Then cells were ﬁxed, stained and the number of
colonies quantiﬁed. 361C cells bypassed more efﬁciently
the barriers of low-density seeding than 361shTRIB
cells, as the latter generated a signiﬁcantly reduced
number of colonies in this assay (Figure 5c). These data
have been conﬁrmed for different cell clones. Further-
more, re-expression of mouse trb2, which is resistant to
the stable silencing in 361shTRIB cells, was sufﬁcient to
rescue the aggressive phenotype of 361C cells, thereby
unambiguously relating these observations to the silen-
cing of TRIB2.
The ability of 361C or 361shTRIB cells to grow in
anchorage-independent conditions was analyzed by
seeding 105 cells in soft agar and allowing them to grow
for 1 month. Importantly, 361C cells produced a
signiﬁcantly greater number of foci than 361shTRIB
cells (Figure 5d). Furthermore, the foci formed by 361C
cells showed increased size (Figure 5e).
To investigate the inﬂuence of TRIB2 in the migration
properties of melanoma cells, both cell lines were seeded
in 24-well plates and allowed to reach conﬂuence. At
that point, a wound was produced in the central vertical
axis of each well and a ﬁxed point of reference for
microscopic photography was set. Pictures taken every
24 h indicated a greater efﬁciency of 361C cells in
reﬁlling the wounded area, closing the wound over a
period of 72 h, whereas 361shTRIB cells were unable to
reﬁll the wounded area even after 96 h (Figure 5f).
Furthermore, 361shTRIB cells showed contact inhibi-
tion upon reaching conﬂuence, whereas 361C cells piled
up and formed colonies beyond the cell monolayer,
a feature of transformed cells (Figure 5f). Taken together,
these results support the hypothesis that TRIB2 is necessary
for the maintenance of the tumorigenic properties of
melanoma cells.
TRIB2 knockdown impairs melanoma growth in vivo
To investigate the possible effects of TRIB2 knockdown
in settings that resemble with more ﬁdelity in vivo
tumorigenesis, 7 105 361C or 361shTRIB cells, respec-
tively, were xenografted subcutaneously in ZSCID mice,
and their respective tumor growth was followed over a
period of 10 weeks. Tumor development occurred
signiﬁcantly faster in mice injected with control
cells (361C) when compared with animals in which
TRIB2 knockdown cells (361shTRIB) were implanted
(Figure 6a). On day 69, pictures taken from the animals
before killing and after tumor resection show a clear
difference in the in vivo growth potential of the cell
populations implanted (Figure 6b). Whereas 361C cells
produced larger, spherical tumors, 361shTRIB cells
rarely grew beyond a few mm3.
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Figure 4 TRIB2 expression negatively correlates with Bim expression and nuclear FOXO localization. qRT–PCR analysis of TRIB2
(a) and Bim (b) mRNA levels in a panel of cell lines. Black bars refer to melanocyte-derived cells, while white bars correspond to non-
melanocyte derived cells. Error bars refer to standard error. Normalization of the results was performed by taking 18S mRNA levels as
reference. (c) Subcellular localization of ﬂuorescently labeled FOXO reporter protein stably expressed in HaCaT keratinocytes and in
the melanoma cell lines Sk-Mel-28, UACC-62 and M-14. Representative images are shown.
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Figure 5 Silencing of TRIB2 decreases the malignant phenotype of melanoma cells. (a) qRT–PCR analysis of TRIB2 mRNA levels in
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Discussion
The advent of RNAi-based functional genomics in
mammals paved the way for unbiased screens in human
cell systems. In the present work we report a large-scale
loss of function screen aimed to identify and validate gene
targets involved in the framework of signalling events that
control the activity of FOXO transcription factors.
Based on two independent cell-based systems that
were shown to effectively report FOXO-dependent
transcriptional activity and subcellular localization of
the GFP–FOXO fusion protein, we screened a vector-
based RNAi expression library that directs the synthesis
of shRNAs targeting for suppression 7914 different
human genes. Those genes of which silencing produced
positive hits in both screening systems were included in
the high conﬁdence list of FOXO suppressors. Among
the selected genes were PIK3CA and Akt-3, components
of the canonical PI3K/Akt pathway. Interestingly,
silencing of the Ca2þ -binding protein Calmodulin 2
increased FOXO-driven luciferase activity and induced
nuclear translocation of the GFP–FOXO reporter
protein. These data are in agreement with the previous
observation that inhibition of Calmodulin by its speciﬁc
small-molecule inhibitors W7, W13 and Calmidazol led
to the nuclear accumulation of FOXO (Zanella et al.,
2008) and strengthens the notion that calcium signaling
is an important factor inﬂuencing the subcellular
localization of FOXO. The presence within our priority
list of genes that are known to be involved in the
regulation of FOXO validated the speciﬁcity of our
screening systems. Among the genes that have not been
previously associated with FOXO functions, we identi-
ﬁed TRIB2, the human homolog of the Drosophila gene
tribbles. Tribbles has been reported to regulate ventral
furrow formation in Drosophila by binding to String or
CDC25 (Grosshans and Wieschaus, 2000; Mata et al.,
2000). The three human orthologs of tribbles, namely
TRIB1, TRIB2 and TRIB3, share a strong similarity in
their amino-acid sequences, consisting essentially in
their pseudokinase domain (Hegedus et al., 2006, 2007).
We found TRIB2 to be highly expressed speciﬁcally in
melanoma malignancies, melanocyte-derived cells and
melanoma cell lines. Interestingly, overexpression was
not observed in samples from other tumor sources,
including non-basal skin carcinoma. Our data suggest a
potential use of TRIB2 as a diagnostic marker for the
detection of malignant melanoma, although more
studies are needed to conﬁrm its utility as a tool in a
diagnostic setting. Further experiments including a
larger patient cohort with survival information must
also elucidate its clinical signiﬁcance.
The regulatory mechanisms that maintain high TRIB2
expression in melanocyte-derived cells remain unknown at
present. TRIB2 expression might be regulated by lineage-
speciﬁc signaling events such as the signal transduction
cascade initiated by c-kit and shown to modulate the
activity and stability of the tissue-restricted dimeric tran-
scription factor MITF (Hou et al., 2000).
Malignant melanoma is one of the most aggressive
human tumors that arise from the malignant transfor-
mation of melanocytes, the pigment-producing cells that
reside in the basal epidermal layer of the human skin.
Several signaling pathways are thought to exert key
functions in melanoma development and progression,
including Ras–Raf–MEK–ERK (MAPK) and the
PI3K/Akt signaling pathways (Meier et al., 2007).
A recent study reported the upregulation of miR-182
in melanoma cell lines and tissue samples promoting the
repression of FOXO3a (Segura et al., 2009). Interest-
ingly, ectopic expression of a non-phosphorylatable,
constitutively nuclear form of FOXO has been shown
to induce apoptosis in A375 melanoma cells (Hilmi
et al., 2008).
In this study, we provide strong evidence for an
alternative mode of FOXO inactivation in melanocyte-
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by unpaired t-test. Except for the time point at day 34, the comparison of the tumor volumes of the two mouse cohorts was statistically
signiﬁcant. The P-values for the time points at days 41–69 were 0.0075, 0.0024, 0.0082, 0.0149 and 0.0080, respectively. (b, c) At day 69,
both groups of animals were photographed, euthanized, and tumors were dissected and photographed. Mice (b) and dissected tumors
(c) representative for the both groups are depicted. The rulers at the bottoms of the photographs (c) are scaled in mm.
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derived and melanoma cells through overexpression of
TRIB2. One appealing possibility is that downregula-
tion of FOXO activity through TRIB2 is one of the
elusive intrinsic survival features of paternal melano-
cytes that determines the aggressive and highly resistant
behavior of melanocyte-derived malignancies nourished
by additional alterations acquired during tumor pro-
gression (Soengas and Lowe, 2003).
In functional assays we could show that suppression
of TRIB2 protein in melanoma cells resulted in a
signiﬁcant decrease in cell proliferation, cell migration
and anchorage-independent growth. Thus, high TRIB2
expression could contribute to the formation and
progression of melanoma lesions. Consistently, retro-
viral expression of TRIB2 has been shown to immorta-
lize hematopoietic progenitors and TRIB2-reconstituted
mice uniformly developed fatal transplantable acute
myelogenous leukemia (Keeshan et al., 2006). Our study
further reveals that in vivo tumor formation of G-361
cells in immunocompromised mice was impaired upon
silencing of TRIB2. Taken together, our data lead to the
conclusion that TRIB2 can promote the growth of
melanoma cells and support their in vivo tumorigenesis.
Future experiments should determine whether TRIB2 is
part of the differentiation program of normal melano-
cytes that predisposes their transformed derivatives to
forming aggressive tumors (Gupta et al., 2005).
In summary, sophisticated cell-based screening sys-
tems allowed us to systematically interrogate the
signaling network that controls the activity of FOXO
proteins and to identify possible targets for the
restoration of FOXO functions, independent of pre-
conceived notions of mechanistic relationships. Our
work identiﬁes TRIB2 as a suppressor of FOXO activity
overexpressed in malignant melanoma and provides
evidence that TRIB2 contributes to the maintenance of
the malignant phenotype of melanoma cells. Thus,
further investigation into the role of TRIB2 in the
pathogenesis of melanoma lesions may provide new
therapeutic insights into this most aggressive form of
skin cancer resistant to all standard anticancer therapies.
Materials and methods
Reagents and plasmids
LY294002 was purchased from Calbiochem (San Diego, CA,
USA). Human insulin was purchased from Roche Diagnostics
(Mannheim, Germany). The NKI shRNA libray was provided
by R Bernards. The RNAi agents to validate TRIB2 silencing
were purchased from Applied Biosystems (Foster City, CA,
USA), Thermo Fisher Scientiﬁc (Waltham, MA, USA) and
OriGene (Rockville, MD, USA). The sequences of the shRNAs
and siRNAs are shown in Supplementary Table S2.
FOXO3a as well as a constitutively active construct,
FOXO3a-(A)3, was kindly provided by Dr M Hu (University
of Texas MD Anderson Cancer Center, Houston, TX, USA).
FOXO1 and FOXO1-GFP were kindly provided by T Unter-
man (University of Illinois at Chicago, Chicago, IL, USA).
TRIB2 cDNA was ampliﬁed from HEK293T cells by
PCR to be cloned into a pCDNA/V5/GW/D-TOPO vector.
Subsequently, PCR was used to amplify TRIB2-V5 and the
resulting fragment was cloned into a pIRESpuro2 vector.
Mouse trb2 was a gift from E Kiss-Toth (University of
Shefﬁeld, Shefﬁeld, UK).
Cell culture
All cell lines were obtained from the American Type Culture
Collection. U2-OS, HEK293T, A375, Hs895T, Sk-Mel-94, Sk-
Mel-19, UACC-257, Hs 895T, Sk-Mel-147, VA-13 and HaCaT
cells were cultivated in Dulbecco’s modiﬁed Eagle’s medium
(Sigma, St Louis, MO, USA), supplied with 10% fetal bovine
serum (FBS). Sk-mel-5, Sk-mel-28, UACC62 and M14 cells
were cultivated in RPMI supplemented with 10% FBS
(Sigma). G-361 cells were maintained in Mc Coy’s 5A medium
complemented with 10% FBS. Previously described U2fox-
RELOC cells (Zanella et al., 2008) were cultivated in 10% FBS
Dulbecco’s modiﬁed Eagle’s medium with 100mg/ml G-418
(Gibco, Paisley, Scotland, UK). Human epidermal melano-
cytes were obtained from Cascade Biologics and maintained in
medium 254 (Cascade Biologics, Portland, OR, USA) supple-
mented with HMGS (Cascade Biologics). Cell cultures were
maintained in a humidiﬁed incubator at 37 1C with 5% CO2.
Generation of 293foxREP cells
HEK293T cells were transfected with the plasmid pGL3-
DBE3X-Luc-Puro (Zanella et al., 2009). Puromycin-resistant
clones were assayed for luciferase activity and responsiveness
to the inhibition of PI3K/Akt signaling. The most suitable
clone was selected as the assay cell line and designated as
293foxREP.
Preparation of the shRNA library
Before its transfection the bacterial cultures of the arrayed
shRNA library were replicated and puriﬁed. The replication
was carried out using a Biomek FX liquid handler (Beckman-
Coulter, Marseille, France). The plasmids contained in the
bacterial cultures were puriﬁed using the Montage plasmid
extraction kit of Millipore (Bedford, MA, USA) adapted to a
vacuum manifold preceded by a preclearing with the Wizard
SV96 lysate clearing plates of Promega (Madison, WI, USA).
Western blot analysis
Cells were lysed with 1ml of a solution containing 50mM Tris-
Cl, 150mM NaCl, 1% Igpal, 10 mg of aprotinin and 10 mg of
leupeptin. After transference, nitrocellulose membranes were
blocked in an infra-red speciﬁc solution (Li-Cor) for a minimum
of 4 h, at 4 1C. Incubation with the primary antibodies was
carried for 4–12h, at 4 1C with constant shaking. TRIB2 levels
were probed using an anti-V5 antibody (Invitrogen, Carlsbad,
CA, USA) and a-tubulin levels were probed as a loading control
with a commercially available antibody (Sigma). All dilutions
used were as indicated in the manufacturers’ instructions.
Luciferase assays
2 105 293foxREP cells were seeded per well in transparent
round-bottom 96-well plates (Nunc, Roskilde, Denmark). Once
attached, cells were co-transfected with 25 ng of the pCDNA3
vector containing cDNA for FOXO3a, 50 ng of the commer-
cially available pRG-TK vector (Promega) containing Renilla
luciferase cDNA for normalization of results and 25ng of the
empty pSuperRetro vector, pSuperRetro containing shRNAs
against PI3K and Akt, or the shRNA pools contained in the
library plate. All transfection experiments were performed in
triplicate, with Effectene transfection reagent (Qiagen, Hilden,
Germany) following the manufacturers’ instructions. Automated
luciferase assays were carried out using the Dual-Luciferase
Human TRIB2 is a repressor of FOXO
F Zanella et al
2980
Oncogene
Reporter Assay System (Promega), according to the manu-
facturer’s instructions.
HCS assays
The workﬂow of the U2foxRELOC assay (Zanella et al., 2008),
as well as the image and data analysis procedures, have been
described previously (Zanella et al., 2007; Rosado et al., 2008).
Cancer-proﬁling array
PCR-ampliﬁed TRIB2 or ubiquitin cDNAs were radioactively
labeled and hybridized subsequently to the Cancer Proﬁling
Array II membrane (BD Biosciences, San Diego, CA, USA).
The washed membrane was exposed to an Amersham Phosphor
Screen overnight and scanned in a Typhoon-9400 Variable
Mode Imager (Amersham Biosciences, Piscataway, NJ, USA).
Quantiﬁcation of the signals was carried in the Quantity One
software version 4.5.2 (BioRad, Mu¨nchen, Germany).
Quantitative RT–PCR
Total RNA was extracted using TRI-Reagent (Sigma),
according to the manufacturers’ indications. After RNA
isolation, DNAse I (Roche) treatment was performed in
the presence of an RNAse inhibitor (Roche, Mannheim,
Germany). Puriﬁed RNAs were quantiﬁed in a NanoDrop
1000 spectrophotometer quality-checked in MOPS-1.2%
agarose gel and cDNA synthesis was carried out using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). PCR reactions were run in an ABI PRISM
7900HT sequence detection system (Applied Biosystems).
Cycling conditions were set to 10min at 95 1C, followed by
40 cycles of 15 s at 95 1C and 1min at 60 1C. Identical PCR
conditions were used with the human melanoma TissueScan
Tissue Quantitative PCR Array (OriGene). Finally, a dissocia-
tion curve was plotted to check the speciﬁcity of ampliﬁcation.
Results were analyzed and the relative mRNA quantity calculated
using the qBasePlus software (Hellemans et al., 2007).
Generation of 361C and 361shTRIB cells
G-361 cells were transfected using the Effectene (Qiagen)
reagent, either with an empty pSuperRetro vector (361C) or
with the validated TRIB2NKI shRNA (361shTRIB). After
selection with Puromycin, both cell populations were main-
tained in Mc Coy’s 5A Medium supplemented with 10% FBS
and 0.5 ug/ml puromycin.
Proliferation and doubling-time assay
At 24 h after seeding 361C and 361shTRIB cells, the growth
medium was changed (day 0) and a point of the curve was taken
every second day. Cells were ﬁxed with 0.5% glutaraldehyde,
stained with 1% crystal violet, lysed with 15% acetic acid and
the lysis products were transferred to clear-bottom 96-well plates
(Nunc). The absorbance at 590nm wavelength was measured in
a Victor3 (Perkin-Elmer, Foster City, CA, USA) plate reader.
Clonogenic assay
361C and 361shTRIB cells were seeded in triplicate at a density
of 104 cells per well in 10-cm plates. The growth medium was
changed every second day. At day 10 cells were ﬁxed with
0.5% glutaraldehyde, stained with 1% crystal violet and the
colonies were counted.
Growth in soft agar
The anchorage-independent growth of 361C and 361shTRIB
cells was analyzed by seeding triplicates of 4 105 cells per well
of each population in 1.4% agarose D-1 Low EEO (Pronadisa)
growth medium containing 10% FBS, and disposed onto a
previously solidiﬁed base of growth medium containing 2.8%
agar (agarose D-1 Low EEO, Pronadisa, Madrid, Spain) in a
six-well plate. Once the soft agar had been solidiﬁed, 1ml of the
growth medium was added. After 24h, media containing 10%
FBS was added to each well and renewed twice weekly. Colonies
were scored after 1 month of growth. Photographs were taken in
an Olympus CK40 microscope equipped with an Olympus DP12
camera (Olympus, Tokyo, Japan) at 40X magniﬁcation.
Wound-healing assays
361C and 361shTRIB cells were seeded in triplicate at a density
of 5 105 cells per well in 24-well plates. Following attach-
ment, a wound was produced in the cell monolayer, the growth
medium was replaced and a picture was taken (day 0) in an
Olympus CK40 microscope equipped with an Olympus DP12
camera at  40 magniﬁcation. Pictures were taken every 24 h
in the same ﬁeld.
Xenografts
ZSCID mice were injected with 7 105 361C and 361shTRIB
cells and the growth of the resulting tumors was followed
by direct measurement of tumour volume every 7 days over
a total period of 69 days. The smallest and the largest
diameter of tumors were measured with a digital caliper, and
tumor volumes were calculated using the following formula:
volume (mm3)¼ [(smallest diameter)2 (largest diameter)]/2.
All values were presented as means±s.e. The unpaired t-test
(two-tailed) was performed for statistical analysis using the
GraphPad PRISM Version 4.0 program.
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